← Eichor
Study identifier: NCT07185841 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Condition: Wet Age-related Macular Degeneration (AMD)  ·  Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd.

PhasePhase 1/Phase 2
Planned participants198
Who can joinAll sexes, 50 Years to 85 Years
Healthy volunteersNo

About this study

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)

This description comes directly from the study's public registry record.

Talk to the study team

Junqing Li  ·  +86 0591-87519936  ·  junqing.li@hxpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07185841